Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Determination of Genetic Relatedness of Linezolid-Resistant VRE Surveillance Cultures
This study is currently recruiting participants.
Verified by University of Pittsburgh, October 2008
Sponsored by: University of Pittsburgh
Information provided by: University of Pittsburgh
ClinicalTrials.gov Identifier: NCT00475891
  Purpose

The study will help in identifying the best empiric antibiotic option for Linezolid resistant VRE infections. This research is important because it allows the determination of resistance rates to antibiotics that may not be frequently tested to by the clinical microbiology laboratory at UPMC-Presbyterian. It also will provide antibiotic minimum inhibitory concentrations (MICs) for these pathogens which may help in identifying the best empiric antibiotic option for Linezolid resistant VRE infections.


Condition
Isolate
Linezolid

MedlinePlus related topics: Antibiotics
Drug Information available for: Linezolid
U.S. FDA Resources
Study Type: Observational
Study Design: Cohort, Retrospective
Official Title: Determination of Genetic Relatedness of Linezolid-Resistant VRE Surveillance Cultures

Further study details as provided by University of Pittsburgh:

Biospecimen Retention:   None Retained

Biospecimen Description:

Estimated Enrollment: 20
Study Start Date: April 2007
Detailed Description:

After 20 linezolid-resistant VRE isolates are identified, genetic relatedness will be determined using a method known as Pulse-field gel electrophoresis (PFGE). No patient related data will accompany these isolates, nor will any related identifiers. These isolates will be tested using standardized susceptibility methods. We will then grow each isolate and test via approved laboratory standards (E-test, AB Biodisk, Stockholm, Sweden) to the drug linezolid. Those determined to be resistant using this approved methodology will be saved until 20 isolates are identified. For resistant isolates found, analytical and molecular techniques will be performed to determine the mechanisms of resistance and whether resistant isolates are coming from a single source/being transmitted from person to person.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

isolates for rectal surveillance

Criteria

Inclusion Criteria:

  • Dr. Harrison's laboratory collected the rectal surveillance isolates for infection control purposes. The isolates will be from January 1, 2006 to December 31, 2006.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00475891

Contacts
Contact: Brian Potoski, Pharm D 412-648-6487 potoskiba@upmc.edu
Contact: Diana Lynn Pakstis, RN, BSN 412-648-6553 pakstisdl@dom.pitt.edu

Locations
United States, Pennsylvania
University of Pittsburgh Medical Center Recruiting
Pittsburgh, Pennsylvania, United States, 15213
Contact: Brian Potoski, Pharm D     412-648-6487     potoskiba@upmc.edu    
Contact: Diana Lynn Pakstis, RN, BSN     412-648-6553     pakstisdl@dom.pitt.edu    
Principal Investigator: Brian Potoski, Pharm D            
Sponsors and Collaborators
University of Pittsburgh
Investigators
Principal Investigator: Brian Potoski, Pharm D University of Pittsburgh
  More Information

Responsible Party: UPMC ( Brian Potoski, Pharm D )
Study ID Numbers: PRO07050007
Study First Received: May 17, 2007
Last Updated: October 3, 2008
ClinicalTrials.gov Identifier: NCT00475891  
Health Authority: United States: Institutional Review Board

Keywords provided by University of Pittsburgh:
isolate
infection
linezolid

Study placed in the following topic categories:
Linezolid

Additional relevant MeSH terms:
Protein Synthesis Inhibitors
Anti-Infective Agents
Molecular Mechanisms of Pharmacological Action
Therapeutic Uses
Enzyme Inhibitors
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 16, 2009